SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* COURY ROBERT J (Last) (First) (Middle) 1000 MYLAN BLVD (Street) CANONSBURG PA 15317 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol MYLAN INC. [ MYL ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Executive Chairman
	3. Date of Earliest Transaction (Month/Day/Year) 01/30/2015
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2015		M		258,564(1)	A	$21.13	1,535,254	D
Common Stock	01/30/2015		S		258,564	D	$53.7283(2)	1,276,690	D
Common Stock	02/02/2015		M		130,203(1)	A	$21.13	1,406,893	D
Common Stock	02/02/2015		M		273,912(3)	A	$22.66	1,680,805	D
Common Stock	02/02/2015		S		404,115	D	$52.8739(4)	1,276,690	D
Common Stock	02/03/2015		M		51,903(3)	A	$22.66	1,328,593	D
Common Stock	02/03/2015		M		181,035(5)	A	$23.44	1,509,628	D
Common Stock	02/03/2015		M		51,502(6)	A	$30.9	1,561,130	D
Common Stock	02/03/2015		S		284,440	D	$51.0135(7)	1,276,690	D
Common Stock								4,957	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option - Right to Buy(8)	$21.13	01/30/2015		M			258,564	(9)	03/03/2020	Common Stock	258,564	$0.00	144,399	D
Employee Stock Option - Right to Buy(8)	$21.13	02/02/2015		M			130,203	(9)	03/03/2020	Common Stock	130,203	$0.00	14,196	D
Employee Stock Option - Right to Buy(8)	$22.66	02/02/2015		M			273,912	(10)	03/02/2021	Common Stock	273,912	$0.00	56,316	D
Employee Stock Option - Right to Buy(8)	$22.66	02/03/2015		M			51,903	(10)	03/02/2021	Common Stock	51,903	$0.00	4,413	D
Employee Stock Option - Right to Buy(8)	$23.44	02/03/2015		M			181,035	(11)	02/22/2022	Common Stock	181,035	$0.00	4,266	D
Employee Stock Option - Right to Buy(8)	$30.9	02/03/2015		M			51,502	(12)	03/06/2023	Common Stock	51,502	$0.00	3,236	D

Explanation of Responses:

1. Represents acquisition of Mylan common stock upon exercise of stock options granted on March 3, 2010.

2. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on January 30, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 403,595 shares in transactions ranging from $53.01 to $54.00 with a weighted average price of $53.5684 as well as 205,341 shares in transactions ranging from $54.005 to $54.25 with a weighted average price of $54.0425. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.

3. Represents acquisition of Mylan common stock upon exercise of stock options granted on March 2, 2011.

4. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 2, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 937,763 shares in transactions ranging from $52.23 to $53.22 with a weighted average price of $52.8646 as well as 13,957 shares in transactions ranging from $53.23 to $53.745 with a weighted average price of $53.5027. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.

5. Represents acquisition of Mylan common stock upon exercise of stock options granted on February 22, 2012.

6. Represents acquisition of Mylan common stock upon exercise of stock options granted on March 6, 2013.

7. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 3, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 520,475 shares in transactions ranging from $52.50 to $53.25 with a weighted average price of $52.8739 as well as 149,400 shares at $53.50 and 1 share at $54.50. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.

8. This option exercise and the related sale of the underlying common stock were executed pursuant to a 10b5-1 trading plan dated November 9, 2014.

9. These options vested in three equal installments on March 3, 2011, 2012, and 2013.

10. These options vested in three equal installments on March 2, 2012, 2013, and 2014.

11. Two thirds of these options vested in equal installments on February 22, 2013 and 2014.

12. One third of these options vested on March 6, 2014.

Remarks:

As disclosed in the proxy statement filed by Mylan Inc. ("Mylan") on December 24, 2014 and the Form 8-K filed by Mylan on November 5, 2014, the filing person has exercised the stock options shown on this Form 4 to mitigate the effects of the excise tax under Section 4985 of the Internal Revenue Code of 1986, as amended, in connection with the proposed acquisition (the "Transaction") by a new public company organized in the Netherlands of both Mylan and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business and has sold the shares reported on this Form 4 to mitigate the tax and other costs imposed as a result of such exercises and the Transaction.

	/s/ Bradley L. Wideman, by power of attorney	02/03/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.